^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-4602

    i
    Other names: SHR-4602, SHR4602, SHR 4602
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Microtubule inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3ms
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Sep 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Yidafan (ivonescimab) • AiRuiLi (adebrelimab) • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    11ms
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Atridia Pty Ltd. | N=20 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    SHR-4602
    1year
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Atridia Pty Ltd. | Initiation date: Nov 2024 --> Mar 2025
    Trial initiation date • Metastases
    |
    SHR-4602
    1year
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Atridia Pty Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SHR-4602
    1year
    A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial • Combination therapy • Metastases
    |
    SHR-4602
    over1year
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Atridia Pty Ltd.
    New P1 trial • Metastases
    |
    SHR-4602
    over1year
    SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial • Metastases
    |
    SHR-4602
    over2years
    A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=133, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    SHR-4602
    over2years
    A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=133, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    SHR-4602